CRISPR Therapeutics AG·4

Oct 17, 5:52 PM ET

Morrow Phuong Khanh 4

4 · CRISPR Therapeutics AG · Filed Oct 17, 2023

Insider Transaction Report

Form 4
Period: 2023-10-13
Morrow Phuong Khanh
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-10-13+16,66716,667 total
    Exercise: $44.31Exp: 2033-10-13Common Shares (16,667 underlying)
Footnotes (1)
  • [F1]This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4